Article
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Clinical colorectal cancer - 1 Jun 2012
Sood Arjun, McClain Danielle, Maitra Radhashree, Basu-Mallick Atrayee, Seetharam Raviraja, Kaubisch Andreas, Rajdev Lakshmi, Mariadason John M, Tanaka Kathryn, Goel Sanjay
Abstract excerpt
PURPOSE: To identify novel genetic markers predictive of clinical benefit from epidermal growth factor receptor-directed antibody therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS: Seventy-six consecutive patients who received cetuximab or panitumumab, either alone or in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.